Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 54 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Keyword is Antibodies, Monoclonal, Humanized [Clear All Filters]
Ofatumumab versus Teriflunomide in Multiple Sclerosis..
N Engl J Med. 383(6), 546-557.
(2020). Real-life efficacy and safety of secukinumab: results from a tertiary hospital in Greece..
J Eur Acad Dermatol Venereol. 33(2), e50-e51.
(2019).
(2018).
Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment..
Expert Opin Ther Targets. 19(3), 299-306.
(2015). Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer..
J Natl Cancer Inst. 107(8),
(2015). PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients..
Cancer Chemother Pharmacol. 75(6), 1289-301.
(2015). Treatment of multiple myeloma bone disease: experimental and clinical data..
Expert Opin Biol Ther. 15(2), 213-30.
(2015). Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer..
Clin Breast Cancer. 14(5), 330-8.
(2014). Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months..
Osteoporos Int. 25(5), 1633-42.
(2014). Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study..
J Dermatolog Treat. 25(1), 73-4.
(2014). Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene)..
J Clin Endocrinol Metab. 99(3), 703-7.
(2014).
(2014). EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab..
J Cancer Res Clin Oncol. 140(5), 737-48.
(2014). In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients..
PLoS One. 9(6), e99131.
(2014). Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study..
Gynecol Endocrinol. 30(8), 587-92.
(2014). Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303..
Clin Cancer Res. 20(11), 3023-32.
(2014). ranibizumab in the management of advanced Coats disease Stages 3B and 4: long-term outcomes..
Retina. 34(11), 2275-81.
(2014).
(2014).
(2014).
(2014). Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes..
BMC Cancer. 13, 49.
(2013). Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial..
J Clin Endocrinol Metab. 98(8), 3206-12.
(2013). Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology..
Future Oncol. 9(4), 505-25.
(2013).
(2013).
(2013).